Creative Medical Technology (NASDAQ:CELZ – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.16), FiscalAI reports.
Creative Medical Technology Trading Up 2.6%
Shares of NASDAQ:CELZ traded up $0.02 during midday trading on Friday, hitting $0.62. The company had a trading volume of 106,318 shares, compared to its average volume of 107,754. Creative Medical Technology has a 12 month low of $0.59 and a 12 month high of $4.72. The firm has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $1.54. The stock has a market cap of $4.10 million, a price-to-earnings ratio of -0.30 and a beta of 2.10.
Wall Street Analyst Weigh In
CELZ has been the subject of several research reports. Weiss Ratings cut Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.
Check Out Our Latest Research Report on Creative Medical Technology
About Creative Medical Technology
Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.
The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.
Featured Stories
- Five stocks we like better than Creative Medical Technology
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
